IP Library Granted Patent US 7,658,943
Granted Patent B2
US 7,658,943 · App. 11/082,720 · Granted Feb 9, 2010

Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,658,943
App. No.
11/082,720
Granted
Feb 9, 2010
Kind
B2
Abstract

The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.

Claims (44)

1. A liquid oral pharmaceutical fill composition for soft capsule dosage form, said composition comprising:

a) vinorelbine or a pharmaceutically acceptable salt thereof in an amount ranging from about 5 mg to about 100 mg per capsule dosage unit;

b) ethanol present in an amount ranging from about 0.3% by weight to about 7.5% by weight of the total weight of the fill composition;

c) water present in an amount ranging from about 1% by weight to about 15% by weight of the total weight of the fill composition; and

d) polyethylene glycol;

wherein the weight ratio of water to ethanol in the fill composition ranges from about 2.3:1 to about 2.7:1.

2. The composition according to claim 1 , wherein said composition further comprises glycerol.

3. The composition according to claim 1 , wherein said soft capsule dosage form is a soft gelatin capsule.

4. The composition according to claim 3 , wherein the gelatin comprises a mixture of porcine gelatin and bovine gelatin.

5. The composition according to claim 2 , wherein said soft capsule dosage form is a soft gelatin capsule.

6. The composition according to claim 5 , wherein the gelatin comprises a mixture of porcine gelatin and bovine gelatin.

7. The composition according to claim 1 , wherein the pharmaceutically acceptable salt of vinorelbine is vinorelbine tartrate.

8. The composition according to claim 2 , wherein the pharmaceutically acceptable salt of vinorelbine is vinorelbine tartrate.

9. The composition according to claim 1 , wherein said polyethylene glycol has an average molecular weight ranging from about 200 to about 600.

10. The composition according to claim 9 , wherein said polyethylene glycol is polyethylene glycol 400.

11. The composition according to claim 2 , wherein said polyethylene glycol has an average molecular weight ranging from about 200 to about 600.

12. The composition according to claim 11 , wherein said polyethylene glycol is polyethylene glycol 400.

13. A liquid oral pharmaceutical fill composition for soft capsule dosage form, said composition comprising:

a) vinorelbine or vinorelbine salt in an amount ranging from about 5 mg to about 100 mg per capsular dosage unit;

b) ethanol present in an amount ranging from about 0.3% by weight to about 7.5% by weight of the total weight of the fill composition;

c) water present in an amount ranging from about 1% by weight to about 15% by weight of the total weight of the fill composition;

d) glycerol present in an amount ranging from about 0.1% by weight to about 20% by weight of the total weight of the fill composition; and

e) polyethylene glycol 400 present in an amount ranging from about 66% by weight to about 78% by weight of the total weight of the fill composition;

wherein the weight ratio of water to ethanol in the fill composition ranges from about 2.3:1 to about 2.7:1.

14. The composition according to claim 13 , wherein said composition comprises ethanol in an amount ranging from about 1.6% by weight to about 5% by weight of the total weight of the fill composition and glycerol in an amount ranging from about 0.2% by weight to about 12% by weight of the total weight of the fill composition.

15. The composition according to claim 14 , wherein the weight ratio of water to ethanol is about 2.5:1.

16. A liquid oral pharmaceutical fill composition for soft capsule dosage form, said composition comprising:

a) about 15.8% by weight vinorelbine tartrate;

b) about 2.9% by weight ethanol;

c) about 7.1% by weight water;

d) about 1.1% by weight glycerol; and

e) about 73.1% by weight polyethylene glycol 400;

wherein the weight ratio of water to ethanol in the fill composition ranges from about 2.3:1 to about 2.7:1.

17. A method of treating cancers responsive to vinorelbine or a pharmaceutically acceptable salt thereof comprising orally administering to a patient in need of said treatment a liquid oral pharmaceutical composition in soft capsule dosage form, said composition comprising:

a) vinorelbine or a pharmaceutically acceptable salt thereof in an amount ranging from about 5 mg to about 100 mg per capsule dosage unit;

b) ethanol present in an amount ranging from about 0.3% by weight to about 7.5% by weight of the total weight of the fill composition;

c) water present in an amount ranging from about 1% by weight to about 15% by weight of the total weight of the fill composition; and

d) polyethylene glycol;

wherein the weight ratio of water to ethanol in the fill composition ranges from about 2.3:1 to about 2.7:1.

18. The method according to claim 17 , wherein the composition further comprises glycerol.

19. The method according to claim 17 , wherein the cancer is non-small cell lung cancer or breast cancer.

20. The method according to claim 19 , wherein the breast cancer is metastatic breast cancer.

21. The method according to claim 18 , wherein the cancer is non-small cell lung cancer or breast cancer.

22. The method according to claim 21 , wherein the cancer is metastatic breast cancer.

Assignments (5)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (019323/0302) Recorded Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; R.P. SCHERER TECHNOLOGIES, LLC; R.P. SCHERER CORPORATION
Reel/Frame 069750/0933 →
NOTICE OF SUCCESSION OF AGENCY Recorded May 17, 2019
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049217/0981 →
CHANGE OF NAME Recorded Jan 15, 2010
From: R.P. SCHERER TECHNOLOGIES, INC.
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 023797/0590 →
CHANGE OF NAME Recorded Jul 24, 2007
From: CARDINAL HEALTH 400, INC.; CARDINAL HEALTH 406, LLC; CARDINAL HEALTH 409, INC.; CARDINAL HEALTH 421, INC.; CARDINAL HEALTH PTS, LLC
To: CATALENT USA WOODSTOCK, INC.; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT USA PAINTBALL, INC.; CATALENT PHARMA SOLUTIONS, LLC
Reel/Frame 019588/0622 →
SECURITY AGREEMENT Recorded May 22, 2007
From: PTS ACQUISITION CORP.; PTS INTERMEDIATE HOLDINGS LLC; CARDINAL HEALTH 400, INC.; CARDINAL HEALTH 406, LLC; CARDINAL HEALTH 421, INC.; CARDINAL HEALTH PTS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; GLACIER CORPORATION; CARDINAL HEALTH 409, INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 019323/0302 →